In line with our vision, Atturos is committed to developing tests that allow patients and clinicians to make better decisions based on solid science. Using the data we generated over a number of years, we are actively pursuing the characterisation and validation protein biomarkers that indicate the onset of disease and/or responses to treatment
Our intention, subject to continued robust validation, is to deliver the OCProDx test to routine practice to improve clinical and patient decisions in prostate cancer. Atturos plan to commercialise the OCProDx test in late 2022. Our goal is to give patients and clinicians clearer information to help them make guided treatment decisions.
Our longer term vision is to integrate molecular diagnostics into decision making tools to improve the health and quality of life patients while also increasing the cost-effectiveness of healthcare systems. Atturos has ambitious plans for rapid development, growth and internationalisation, and already has a pipeline of other tests in research development.
The existing management team has experience with commercialisation and ambitions to be an integral part of the evolving senior management group of the company while at the same time recognising the need to identify and engage senior experienced executives. The travel and networking associated with the feasibility study will provide an important opportunity to identify such individuals
RAPsA Dx is one of the newer tests currently under development by the team here at Atturos. With the ability to discriminate patients with rheumatoid arthritis from those with psoriatic arthritis, Atturos is excited to begin the next steps in validating this assay.
More information will be added here soon, however please feel free to get in touch if you have any questions in the meantime!
After the successful transfer of PromarkerD from Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a medical technology company headquartered in Perth, Australia, this Laboratory Developed Test (LDT) is being offered in Europe by Atturos.
The following information was taken from the official PromarkerD site and can be accessed here.
PromarkerD Test System
PromarkerD Test System is a blood test that assess the risk of diabetic kidney disease (DKD) in patients with type 2 diabetes. It is a simple blood test that measure a panel of three novel plasma biomarkers combined with 3 clinical factors.
How it Works
Plasma sample analysis to measure the concentration of a panel of three novel protein biomarkers (ApoA4, CD5L and IBP3). The biomarker concentrations are combined with 3 clinical factors (age, HDL-cholesterol and eGFR) measured at the time of the test. The combined raw data is submitted to the PromarkerD Hub, and a test report is generated.
The Promarker™ platform identified a panel of novel protein markers (biomarkers) that are significantly effective in diagnosing and predicting diabetic kidney disease. There biomarkers include ApoA4, CD5L and IBP3. The ability of the biomarkers to diagnose and predict diabetic kidney disease has been studied and verified. In validated clinical studies, the PromarkerD test system predicted 86% of otherwise healthy diabetics who went on to develop DKD within four years.
PromarkerD Hub is a software tool that contains a proprietary algorithm used to calculate the risk of DKD.